|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Kalim, S, Clish, CB, Wenger, J, Elmariah, S, Yeh, RW, Deferio, JJ, Pierce, K, Deik, A, Gerszten, RE, Thadhani, R, Rhee, EP|
|Journal||J Am Heart Assoc|
|Date Published||2013 Dec 05|
|Keywords||Aged, Aged, 80 and over, Biomarkers, Cardiovascular Diseases, Carnitine, Case-Control Studies, Chi-Square Distribution, Chromatography, Liquid, Female, Humans, Kidney Failure, Chronic, Logistic Models, Male, Mass Spectrometry, Metabolomics, Middle Aged, Multivariate Analysis, Odds Ratio, Prospective Studies, Renal Dialysis, Risk Factors, Time Factors, Treatment Outcome, Uremia|
BACKGROUND: The marked excess in cardiovascular mortality that results from uremia remains poorly understood.
METHODS AND RESULTS: In 2 independent, nested case-control studies, we applied liquid chromatography-mass spectrometry-based metabolite profiling to plasma obtained from participants of a large cohort of incident hemodialysis patients. First, 100 individuals who died of a cardiovascular cause within 1 year of initiating hemodialysis (cases) were randomly selected along with 100 individuals who survived for at least 1 year (controls), matched for age, sex, and race. Four highly intercorrelated long-chain acylcarnitines achieved the significance threshold adjusted for multiple testing (P
CONCLUSIONS: Our data highlight clinically meaningful alterations in acylcarnitine homeostasis at the time of dialysis initiation, which may represent an early marker, effector, or both of uremic cardiovascular risk.
|Alternate Journal||J Am Heart Assoc|
|PubMed Central ID||PMC3886735|
|Grant List||K08 DK090142 / DK / NIDDK NIH HHS / United States |
K24 DK094872 / DK / NIDDK NIH HHS / United States
K08-DK-090142 / DK / NIDDK NIH HHS / United States
R21-DK-071674 / DK / NIDDK NIH HHS / United States